StocktoriaJaguar Health, Inc. JAGX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M |
| Operating income | -$45.9M | -$30.8M | -$34.3M | -$34.4M | -$40.7M |
| Net income | -$53.6M | -$38.5M | -$41.3M | -$47.5M | — |
| Operating cash flow | -$23.7M | -$29.4M | -$33.2M | -$33.1M | -$35.0M |
| Free cash flow | — | -$29.4M | — | -$33.2M | -$35.0M |
| Total assets | $38.3M | $53.4M | $50.8M | $47.5M | $53.3M |
| Total liabilities | $57.0M | $44.4M | $45.9M | $48.8M | $41.4M |
| Shareholders' equity | -$18.7M | $6.5M | $4.9M | -$1.4M | $11.9M |
| Ratios | |||||
| Operating margin | -398.8% | -263.8% | -351.3% | -287.8% | -939.1% |
| Net margin | -465.4% | -329.3% | -423.1% | -396.9% | — |
| FCF margin | — | -251.5% | — | -277.5% | -806.8% |
| Return on assets | -139.8% | -72.0% | -81.4% | -100.0% | — |
| Return on equity | 286.7% | -592.7% | -843.4% | 3491.8% | — |
| Current ratio | 0.50 | 1.63 | 2.00 | 0.74 | 1.84 |
| Revenue growth | -1.5% | 19.8% | -18.4% | 175.8% | -53.8% |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001585608 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.